Muronomab-CD3 for pediatric acute myocarditis

Pediatric Cardiology

Volumn 28, Issue 1, 2007, Pages 21-26

  Perens, Gregory ^a   Levi, Daniel S ^a   Alejos, Juan Carlos ^a   Wetzel, Glenn T ^b  

^a UCLA MEDICAL CENTER   (United States)

^b UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

Immunosuppression; Myocarditis; OKT3

Indexed keywords

IMMUNOGLOBULIN G; METHYLPREDNISOLONE SODIUM SUCCINATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OKT 3; PREDNISONE; STEROID; TACROLIMUS;

ADOLESCENT; ADULT; CARDIAC GRAFT REJECTION; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; ECHOCARDIOGRAPHY; EXTRACORPOREAL OXYGENATION; GASTROINTESTINAL DISEASE; HEART ARRHYTHMIA; HEART FAILURE; HEART HEMODYNAMICS; HEART LEFT VENTRICLE EJECTION FRACTION; HEART MUSCLE BIOPSY; HEART TRANSPLANTATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFANT; MEDICAL RECORD REVIEW; MYOCARDITIS; REVIEW;

ACUTE DISEASE; ADOLESCENT; CHILD; CHILD, PRESCHOOL; EXTRACORPOREAL MEMBRANE OXYGENATION; HEART FAILURE, CONGESTIVE; HEART VENTRICLES; HEART-ASSIST DEVICES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFANT; MUROMONAB-CD3; MYOCARDITIS; PEDIATRICS; RETROSPECTIVE STUDIES; STROKE VOLUME; TREATMENT OUTCOME;

EID: 33847199752     PISSN: 01720643     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00246-006-1322-3     Document Type: Review

References (27)

1. Ahdoot J, Galindo A, Alejos JC, et al. (2000) Use of OKT3 for acute myocarditis in infants and children. J Heart Lung Transplant 19:1118-1121
2. Aretz HT (1987) Myocarditis: the Dallas criteria. Hum Pathol 18:619-624
3. Costello JM, Pahl E (2002) Prevention and treatment of severe hemodyjnamic compromise in pediatric heart transplant patients. Paediatr Drugs 4:705-715
4. Drucker NA, Colan SD, Lewis AB, et al. (1994) Gamma-globulin treatment of acute myocarditis in the pediatric population. Circulation 89:252-257
5. English RF, Janosky JE, Ettedgui JA, Webber SA (2004) Outcomes for children with acute myocarditis. Cardiol Young 14:488-493
6. Feldman AM, McNamara D (2000) Myocarditis. N Engl J Med 343:1388-1398
7. Fohlman J, Pauksen K, Morein B, et al. (1993) High yield production of an inactivated coxsackie B3 adjuvant vaccine with protective effect against experimental myocarditis. Scand J Infect Dis 88(Suppl):103-108
8. Gagliardi MG, Bevilacqua M, Bassano C, et al. (2004) Long term follow up of children with myocarditis treated by immunosuppression and of children with dilated cardiomyopathy. Heart 90:1167-1171
9. + T lymphocytes in coxsackie B3-induced viral myocarditis. J Virol 69:6720-6728
10. Inomata T, Watanabe T, Haga M, et al. (2000) Anti-CD2 monoclonal antibodies prevent the induction of experimental autoimmune myocarditis. Jpn Heart J 41:507-517
11. Jett GK, Miller A, Savino D, Gonwa T (1992) Reversal of acute fulminant lymphocytic myocarditis with combined technology of OKT3 monoclonal antibody and mechanical circulatory support. J Heart Lung Transplant 11(4 Pt 1):733-738
12. Kawai C (1999) From myocarditis to cardiomyopathy; mechanisms of inflammation and cell death: learning from the past for the future. Circulation 99:1091-1100
13. Kishimoto C, Abelmann WH (1989) Monoclonal antibody therapy for prevention of acute coxsackievirus B3 myocarditis in mice. Circulation 79:1300-1308
14. Kishimoto C, Kuribayashi K, Masuda T, Tomioka N, Kawai C (1985) Immunologic behavior of lymphocytes in experimental viral myocarditis: significance of T lymphocytes in the severity of myocarditis and silent myocarditis in BALB/c-nu/nu mice. Circulation 71:1247-1254
15. Levi D, Alejos J (2001) Diagnosis and treatment of pediatric viral myocarditis. Curr Opin Cardiol 16:77-43
16. Maejima Y, Yasu T, Kubo N, et al. (2004) Long-term prognosis of fulminant myocarditis rescued by percutaneous cardiopulmonary support device. Circ J 68:829-833
17. Mason JW O'Connell JB, Herskowitz A, et al. (1995) A clinical trial of immunosuppressive therapy for myocarditis. The Myocarditis Treatment Trial Investigators. N Engl J Med 333:269-275
18. Menghini VV, Savcenko V, Olson LJ, et al. (1999) Combined imnunosuppression for the treatment of idiopathic giant cell myocarditis. Mayo Clinic Proc 74:1221-1226
19. Oh CS, Stratta RJ, Fox BC, et al. (1988) Increased infections associated with the use of OKT3 for treatment of steroid-resistant rejection in renal transplantation. Transplantation 45:68-73
20. Opavsky MA, Penninger J, Aitken K, et al. (1999) Susceptibility to myocarditis is dependent on the response of alphabeta lymphocytes to coxsackie infection. Circ Res 85:551-558
21. Pinderski LJ, Fonarow GC, Hamilton M, et al. (2002) Giant cell myocarditis in a young man responsive to T-lymphocyte cytolytic therapy. J Heart Lung Transplant 21:818-821
22. Renders L, Valerius T (2003) Engineered CD3 antibodies for immunosuppression. Clin Exp Immunol 133:307-309
23. Rotbart HA (1999) Antiviral therapy for enteroviral infections. Pediatr Infect Dis J 18:632-633
24. Sgro C (1995) Side-effects of monoclonal antibody, muromonab CD3/orthoclone OKT3: bibliographic review. Toxicology 105:23-29
25. Torres F, Anguita M, Tejero I, et al. (1995) Acute myocarditis with severe cardiac dysfunction in the pediatric population. The evolution and differential characteristics with respect to adult myocarditis. Rev Esp Cardiol 48:660-665
26. Wilde MI, Goa KL (1996) Muromonab CD3: a reappraisal of its pharmacology and use as prophylaxis of solid organ transplant rejection. Drugs 51:865-894
27. Woodruff JF, Woodruff JJ (1974) Involvement of T lymphocytes in the pathogenesis of coxsackie virus B3 heart disease. J Immunol 113:1726-1734